The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost controls amid challenges in the obesity-drug market.

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, the company said on Wednesday.

Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate NVO stock a Buy now.

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's workforce nearly doubled in five years, but slowing sales and increased competition are now putting pressure on costs.

COPENHAGEN, DENMARK (Reuters) -Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that are not critical for its business, the company said on Wednesday. "We currently have a hiring freeze in non-business critical areas,

Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs and regain its footing in the competitive market.

BioMed X & Novo Nordisk launch new collaboration in oral peptide drug delivery: Heidelberg, Germany Thursday, August 21, 2025, 12:00 Hrs [IST] BioMed X, an independent biomedical

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this stock may double in 5 years.